SAN DIEGO, Nov. 27 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that it will present at the Lazard Capital Markets Third Annual Life Sciences Conference on Wednesday, November 29, 2006 at 3:00 p.m. EST (12:00 p.m. PST) at the New York Palace Hotel. It will also present at the Piper Jaffray 18th Annual Healthcare Conference on Friday, December 1, 2006 at 2:00 p.m. EST (11:00 a.m. PST) at The Pierre New York Hotel.
Kleanthis G. Xanthopoulos, Ph.D., Anadys’ President Emeritus and a member of the Board of Directors, and Lawrence C. Fritz, Ph.D., Anadys’ newly appointed President and Chief Executive Officer, will present an overview of Anadys and its clinical development and discovery programs at both conferences.
Each presentation will be simultaneously webcast and can be accessed on the Company’s website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to each of the corporate presentations to download or install any necessary software. A replay of the presentations will become available approximately one hour after the live webcast concludes. Replays of both presentations will be archived and available until December 15, 2006.
About Anadys
Anadys Pharmaceuticals, Inc., www.anadyspharma.com, is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company has core expertise in structure-based drug design coupled with medicinal chemistry and Toll-Like Receptor-based small molecule therapeutics. Anadys’ clinical development programs include ANA380 for the treatment of HBV, currently in mid-stage clinical development, and ANA975 for the treatment of HCV and HBV, which was suspended while in Phase Ib clinical trials due to pre-clinical toxicology observations in animals. The IND covering ANA975 is currently on full clinical hold; however, a new pre-clinical study has been initiated as a step toward the objective to resume the ANA975 clinical program. Overall, Anadys’ therapeutic platform is designed to advance a strong and continual pipeline of drug candidates into the clinic.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys’ actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. In particular, there is no guarantee that the FDA will lift the clinical hold on the ANA975 IND, that Anadys and Novartis will be able to agree on future development activities for ANA975 or that the clinical development of ANA975 will be able to be resumed. In addition, the results of initial clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Furthermore, Anadys’ results may be affected by risks related to its collaborative relationships with Novartis and LG Life Sciences, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, the level of effort that its collaborative partners devote to development and commercialization of its product candidates, difficulties or delays in its pre-clinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. These and other factors that may cause actual results to differ are more fully discussed in Anadys’ SEC filings, including Anadys’ Form 10-K for the year ended December 31, 2005 and the “Risk Factors” section of Anadys’ Form 10-Q for the quarter ended September 30, 2006. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Anadys Pharmaceuticals, Inc.
CONTACT: Vince Reardon, Sr. Director, Investor Relations & CorporateCommunications of Anadys Pharmaceuticals, Inc., +1-858-530-3653,vreardon@anadyspharma.com
Web site: http://www.anadyspharma.com/
